AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25329433 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week exercise intervention (light-to-moderate-intensity aerobic and resistance exercises, mainly leg press, 3 sessions per week)
Number of subjects: 20
Study 25329433 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week detraining period
Number of subjects: 20
Study 25329433 — intervention group
Group type: COMPARATOR
Intervention: Standard-care (control) group
Number of subjects: 20
Study 24354616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal PRP after FCL
Number of subjects: 30
Study 24354616 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical PRP after FCL
Number of subjects: 30
Study 24354616 — intervention group
Group type: COMPARATOR
Intervention: FCL alone
Number of subjects: 30
Study 24354616 — intervention group
Group type: COMPARATOR
Intervention: ID saline after FCL
Number of subjects: 30
Study 21894411 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation weaning protocol using spontaneous breathing trial
Number of subjects: 36
Study 21894411 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation weaning without a standardized protocol (Control)
Number of subjects: 36
Study 19301380 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori eradication treatment (standard protocol)
Number of subjects: 55
Study 19301380 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment (control group)
Number of subjects: 55
Study 17133405 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine 100 mg/m(2) per course every 4 weeks in 3 different schedules: 1) 20 mg/m(2) intravenously daily x 5, 2) 20 mg/m(2) subcutaneously daily x 5, and 3) 10 mg/m(2) intravenously daily x 10
Number of subjects: 115
Study 15170007 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin, 0.5 mg/kg daily for 12 weeks
Number of subjects: 60
Study 15170007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11789362 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide 50 mg/day
Number of subjects: 150
Study 11789362 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide and potassium citrate
Number of subjects: 150
Study 11789362 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control Group A)
Number of subjects: 150
Study 9440763 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene
Number of subjects: 0
Study 9440763 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 9440763 — intervention group
Group type: EXPERIMENTAL
Intervention: Both agents
Number of subjects: 0
Study 8283158 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 2046
Study 8283158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2046
Study 29080299 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine-based therapy
Number of subjects: 534
Study 26631773 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic grafts
Number of subjects: 100
Study 26631773 — intervention group
Group type: COMPARATOR
Intervention: Autologous veins
Number of subjects: 100
Study 25241369 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 as distension media
Number of subjects: 392
Study 25241369 — intervention group
Group type: COMPARATOR
Intervention: Normal saline as distension media
Number of subjects: 392
Study 25241369 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS>3 group
Number of subjects: 392
Study 25241369 — intervention group
Group type: COMPARATOR
Intervention: VAS≤3 group
Number of subjects: 392
Study 25241369 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 392
Study 24325953 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane catheter delivering intermittent local anesthetic
Number of subjects: 0
Study 24325953 — intervention group
Group type: COMPARATOR
Intervention: Patient‐controlled anesthesia device delivering intravenous opioids (Control)
Number of subjects: 0
Study 20963271 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater social-environmental support for disease management
Number of subjects: 0
Study 20963271 — intervention group
Group type: EXPERIMENTAL
Intervention: Less depressive symptomatology
Number of subjects: 0
Study 19789522 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol - Remifentanil
Number of subjects: 33
Study 19789522 — intervention group
Group type: COMPARATOR
Intervention: Propofol - Alfentanil
Number of subjects: 33
Study 16461376 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip (HG) exercise at 70% of maximum voluntary contraction
Number of subjects: 20
Study 16461376 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip (HG) exercise at 50% of maximum voluntary contraction
Number of subjects: 20
Study 16461376 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps contraction (QC) exercise
Number of subjects: 20
Study 16461376 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-HG circulatory responses
Number of subjects: 20
Study 15876979 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium antagonists (nitrendipine)
Number of subjects: 0
Study 15876979 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive regimens (various classes)
Number of subjects: 0
Study 11905711 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative (neoadjuvant) medical therapy
Number of subjects: 0
Study 9137021 — intervention group
Group type: EXPERIMENTAL
Intervention: Biojector (needleless injection system)
Number of subjects: 74
Study 9137021 — intervention group
Group type: COMPARATOR
Intervention: Needle injections
Number of subjects: 74
Study 8194308 — intervention group
Group type: EXPERIMENTAL
Intervention: RMNP2 program for non-parametric analysis of repeated measures
Number of subjects: 0
Study 3796171 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose amoxicillin (100 mg/kg) followed by placebo every 8 hours for 10 days
Number of subjects: 17
Study 3796171 — intervention group
Group type: COMPARATOR
Intervention: 10-day course of amoxicillin (40 mg/kg/D)
Number of subjects: 17
Study 31986338 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exposure to PM10 during the three months preconception
Number of subjects: 10686
Study 31986338 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exposure to PM10 during the first trimester
Number of subjects: 10686
Study 31986338 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exposure to PM10 from the third month before pregnancy to the third month after pregnancy
Number of subjects: 10686
Study 29499393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecological momentary assessments (EMA)
Number of subjects: 43
Study 29499393 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAID classification of EMAs into six levels of risk
Number of subjects: 43
Study 26494768 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Diagnosis and Therapy (MDT)
Number of subjects: 140
Study 26494768 — intervention group
Group type: COMPARATOR
Intervention: Back School
Number of subjects: 140
Study 26582405 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid for 5 consecutive days
Number of subjects: 300
Study 26582405 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 consecutive days
Number of subjects: 300
Study 26582405 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanic acid
Number of subjects: 300
Study 26582405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 23731081 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy
Number of subjects: 60
Study 23731081 — intervention group
Group type: COMPARATOR
Intervention: Four-port laparoscopic cholecystectomy
Number of subjects: 60
Study 20575290 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (10,000 U/kg after skin incision, 5,000 U/kg after operation on days 1, 2, 3)
Number of subjects: 40
Study 20575290 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 40
Study 19865633 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched implants
Number of subjects: 45
Study 19865633 — intervention group
Group type: COMPARATOR
Intervention: External-hexagon implants
Number of subjects: 45
Study 15733514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol
Number of subjects: 24
Study 15733514 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol from MDI
Number of subjects: 24
Study 15733514 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic cream applied to face
Number of subjects: 24
Study 15733514 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthetic cream applied to back of hand
Number of subjects: 24
Study 12874415 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month treatment with IV anti-T-lymphocyte immunoglobulin followed by oral methotrexate 7.5 mg/week (ATG group)
Number of subjects: 11
Study 12874415 — intervention group
Group type: COMPARATOR
Intervention: 12-month treatment with oral methotrexate 7.5 mg/week alone (MTX group)
Number of subjects: 11
Study 10369711 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 100 microg, subcutaneous injection three times daily for seven days
Number of subjects: 302
Study 10369711 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 200 microg, subcutaneous injection three times daily for seven days
Number of subjects: 302
Study 10369711 — intervention group
Group type: COMPARATOR
Intervention: Placebo, subcutaneous injection three times daily for seven days
Number of subjects: 302
Study 10369711 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (Octreotide and Placebo)
Number of subjects: 302
Study 8899313 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain monotherapy
Number of subjects: 96
Study 8899313 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil (5‐FU) and X‐ray therapy
Number of subjects: 96
Study 1893902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-country skiing training for 9-10 weeks, 40-min sessions, 3 times a week at 75%-85% VO2max
Number of subjects: 66
Study 1893902 — intervention group
Group type: EXPERIMENTAL
Intervention: Running training for 9-10 weeks, 40-min sessions, 3 times a week at 75%-85% VO2max
Number of subjects: 66
Study 1893902 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 66
Study 1893902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise groups (skiing and running)
Number of subjects: 66
Study 1893902 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (skiing, running, control)
Number of subjects: 66
Study 6407749 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) for 4 malnourished children for 28 days
Number of subjects: 18
Study 6407749 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral parenteral nutrition plus enteral nutrition for 4 malnourished children for 28 days
Number of subjects: 18
Study 6407749 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive enteral nutrition program for 7 nourished children
Number of subjects: 18
Study 6407749 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) for 2 nourished children
Number of subjects: 18
Study 6407749 — intervention group
Group type: EXPERIMENTAL
Intervention: Nourished children at diagnosis
Number of subjects: 18
Study 6407749 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnourished children at diagnosis
Number of subjects: 18
Study 6407749 — intervention group
Group type: EXPERIMENTAL
Intervention: Nourished or becoming renourished during the first 21 days of therapy
Number of subjects: 18
Study 6407749 — intervention group
Group type: EXPERIMENTAL
Intervention: Becoming malnourished or remaining malnourished during the first 21 days of therapy
Number of subjects: 18
Study 30914102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium acetate Ringer solution infusion (group A: 4 mL·kg‐1·h‐1, group B: increased by 50%, group C: increased by 100%) for 30 minutes
Number of subjects: 26
Study 30914102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium acetate Ringer solution infusion (group B)
Number of subjects: 26
Study 30914102 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium acetate Ringer solution infusion (group A)
Number of subjects: 26
Study 28012569 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (MPA) 80 mg, 2 mL
Number of subjects: 100
Study 28012569 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA) 80 mg, 2 mL
Number of subjects: 100
Study 28012569 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (MPA)
Number of subjects: 100
Study 28012569 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 100
Study 28012569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MPA and TA
Number of subjects: 100
Study 25875954 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy with intrapericardial tube (study group)
Number of subjects: 210
Study 25875954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pericardial space intervention)
Number of subjects: 210
Study 25161294 — intervention group
Group type: EXPERIMENTAL
Intervention: cilostazol
Number of subjects: 14
Study 25161294 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 22393902 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mmHg stepwise balloon distensions
Number of subjects: 60
Study 22393902 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic compliance
Number of subjects: 60
Study 19384218 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (100 mg/kg bolus; 20 mg.kg.hr infusion until 4 hours after cardiopulmonary bypass)
Number of subjects: 177
Study 19384218 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 177
Study 19384218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 17906573 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc at 1 level
Number of subjects: 59
Study 17906573 — intervention group
Group type: EXPERIMENTAL
Intervention: ProDisc at 2 levels
Number of subjects: 59
Study 15121491 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (mean dose 32 +/- 16 mg)
Number of subjects: 93
Study 15121491 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 93
Study 11299253 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 40
Study 11299253 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 40
Study 11299253 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 40
Study 10374446 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchofiberscope and catheter intervention with ofloxacin and amikacin
Number of subjects: 48
Study 10374446 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 48
Study 7949085 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐6 isolation from bone marrow samples of patients with idiopathic BM suppression (IBMS)
Number of subjects: 15
Study 7949085 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐6 isolation from bone marrow samples of patients with diagnosed BM suppression (DBMS)
Number of subjects: 15
Study 7949085 — intervention group
Group type: COMPARATOR
Intervention: HHV‐6 isolation from control BM samples from another population of BMT patients
Number of subjects: 15
Study 3128767 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam
Number of subjects: 30
Study 3128767 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin and Azlocillin (Control)
Number of subjects: 30
Study 31891288 — intervention group
Group type: COMPARATOR
Intervention: HLA‐DRB1*13 allele
Number of subjects: 165
Study 31891288 — intervention group
Group type: COMPARATOR
Intervention: HLA‐DRB1*09 allele
Number of subjects: 165
Study 30638544 — intervention group
Group type: EXPERIMENTAL
Intervention: Liothyronine (T3) therapy (maximum dosage 15 mcg/m2/die)
Number of subjects: 37
Study 30638544 — intervention group
Group type: EXPERIMENTAL
Intervention: Liothyronine (T3) therapy (T3-treated group)
Number of subjects: 37
Study 30638544 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 37
Study 30638544 — intervention group
Group type: COMPARATOR
Intervention: Comparison between T3-treated and untreated groups
Number of subjects: 37
Study 27666144 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-reference radiologists' grading of VUR
Number of subjects: 602
Study 27666144 — intervention group
Group type: COMPARATOR
Intervention: Reference radiologists' adjudicated grading of VUR
Number of subjects: 602
Study 27666144 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-reference radiologists' grading of VUR compared to reference radiologists' adjudicated grade
Number of subjects: 602
Study 27666144 — intervention group
Group type: EXPERIMENTAL
Intervention: Agreement on VUR grade when participant was the unit of analysis
Number of subjects: 602
Study 27173586 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily
Number of subjects: 252
Study 27173586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 25198275 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion for less than 12 hours
Number of subjects: 933
Study 25198275 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion for 12-18 hours
Number of subjects: 933
Study 25198275 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion for greater than 18 hours
Number of subjects: 933
Study 25198275 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate infusion (all durations)
Number of subjects: 933
Study 22792882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 89
Study 22792882 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 89
Study 19165617 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally tubeless PCNL (Group 1)
Number of subjects: 90
Study 19165617 — intervention group
Group type: COMPARATOR
Intervention: Standard PCNL with 14F malecot nephrostomy catheter (Group 2)
Number of subjects: 90
Study 17317371 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg
Number of subjects: 306
Study 17317371 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 80 mg
Number of subjects: 306
Study 17317371 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 40 mg (in subjects with low HDL cholesterol)
Number of subjects: 306
Study 17317371 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 80 mg (in subjects with low HDL cholesterol)
Number of subjects: 306
Study 15063607 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 5 mg
Number of subjects: 216
Study 15063607 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 216
Study 15063607 — intervention group
Group type: COMPARATOR
Intervention: placebo/rosuvastatin
Number of subjects: 216
Study 15063607 — intervention group
Group type: COMPARATOR
Intervention: placebo/fenofibrate
Number of subjects: 216
Study 15063607 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/fenofibrate
Number of subjects: 216
Study 11166974 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (0 h)
Number of subjects: 32
Study 11166974 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (3 h)
Number of subjects: 32
Study 11166974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (Methadone patients at 0 h)
Number of subjects: 32
Study 11166974 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (Methadone patients at 3 h)
Number of subjects: 32
Study 11166974 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (Methadone patients at 0 h)
Number of subjects: 32
Study 11166974 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (Methadone patients at 3 h)
Number of subjects: 32
Study 9442174 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin and amniotomy
Number of subjects: 61
Study 9442174 — intervention group
Group type: COMPARATOR
Intervention: Amniotomy only
Number of subjects: 61
Study 9442174 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 61
Study 9442174 — intervention group
Group type: EXPERIMENTAL
Intervention: Both intervention groups (oxytocin and amniotomy, amniotomy only)
Number of subjects: 61
Study 8560369 — intervention group
Group type: EXPERIMENTAL
Intervention: Free screening test provided to the experimental group.
Number of subjects: 81
Study 8560369 — intervention group
Group type: COMPARATOR
Intervention: Control group (no free screening test provided).
Number of subjects: 81
Study 2133472 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment by a dentist
Number of subjects: 55
Study 2133472 — intervention group
Group type: EXPERIMENTAL
Intervention: Craniomandibular disorder treatment group
Number of subjects: 55
Study 2133472 — intervention group
Group type: COMPARATOR
Intervention: Treatment by a neurologist
Number of subjects: 55
Study 330766 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% triamcinolone acetonide (TA)
Number of subjects: 0
Study 330766 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone (HC)
Number of subjects: 0
Study 330766 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 0
Study 28384065 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg every 21 days)
Number of subjects: 427
Study 28384065 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa-2b (5 million units three times per week)
Number of subjects: 427
Study 25554623 — intervention group
Group type: EXPERIMENTAL
Intervention: D-serine (DSR) 2.1 g orally administered
Number of subjects: 35
Study 24283280 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF-silica dentifrice (Aquafresh Advanced, 1,150 ppm F(-))
Number of subjects: 42
Study 24283280 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice (250 ppm F(-), same base)
Number of subjects: 42
Study 24283280 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing duration (45, 60, 120, or 180 seconds)
Number of subjects: 42